The Politics of EU Health Policy and the Case of Direct-to-Consumer Advertising for Prescription Drugs

Abstract

Direct-to-consumer advertising for prescription drugs (DTCA-PD) is currently banned in the EU, but the pharmaceutical industry (supported by key member states and DG Enterprise) made two major attempts to overturn it in the 2000s at the EU level and failed. What does this failure imply for the debates surrounding this policy area and EU health policy in general? To explore this question, this article will define DTCA-PD, examine its pros and cons, provide a brief overview of EU health policy and present a detailed review of the two recent attempts to overturn the ban. Following this, it will examine the five key elements of EU health policy, evaluate their relevance to the development of the EU's policy towards DTCA-PD and briefly speculate on the future of the ban.

Keywords

European Union health policy direct-to-consumer advertising for prescription drugs patient information European policy theories

Get full access to this article

View all access options for this article.

References

Abel-Smith

Figueras

Holland

McKee

and Mossialos

(1995) Choices in Health Policy: An Agenda for the European Union (Aldershot: Dartmouth).

Angell

(2005) The Truth about the Drug Companies: How They Deceive Us and What to Do about it (New York: Random House).

Bonaccorso

and Sturchio

(2002) ‘For and against: Direct to consumer advertising is medicalising normal human experience’, British Medical Journal, 324:7342, 910–911.

Choi

and Lee

(2007) ‘Understanding the impact of direct-to-consumer (DTC) pharmaceutical advertising on patient–physician interactions: Adding the Web to the mix’, Journal of Advertising, 36:3, 137–149.

Coleman

(2004) EU Policies and Programmes Concerning Health: A Short History, Briefing Paper (Belfast: Queen's University Belfast). Available online at: http://www.saglik.gov.tr/extras/dokuman/EU%20Policies%20and%20Programmes.pdf (accessed 11 May 2010).

Commission (2001a) ‘G10 medicines: High level group on innovation and provision of medicines: consultation paper’, September. Available online at: http://ec.europa.eu/enterprise/phabiocom/docs/g10an1.pdf (accessed 11 May 2010).

Commission (2001b) ‘Reform of EU pharmaceutical legislation’, Brussels, 18 July (Memo/01/267). Available online at: http://ec.europa.eu/enterprise/pharmaceuticals/review/doc/brief_m01_267_en.pdf (accessed 11 May 2010).

Commission (2002) ‘Commission gives qualified welcome to European Parliament's vote on pharmaceutical legislation’, Press release, 23 October, IP/02/1545. Available online at: http://europa.eu/rapid/pressReleasesAction.do?reference=IP/02/1545&format=HTML&aged=0&lg=fi&guiLanguage=en (accessed 11 May 2010).

Commission (2007a) ‘Draft report on current practice with regard to provision of information to patients on medicinal products, Brussels, 19 April. Available online at: http://ec.europa.eu/enterprise/pharmaceuticals/pharmacos/docs/doc2007/2007_04/draft_infopatients2007_04.pdf (accessed 11 May 2010).

10.

Commission (2007b) ‘Report on current practice with regard to provision of information to patients on medicinal products’, Brussels, 20 December, COM (207) 826 final. Available online at: http://ec.europa.eu/enterprise/pharmaceuticals/pharmacos/docs/doc2007/2007_12/inf_to_patients_com_2007_862_en.pdf (accessed 11 May 2010).

11.

Commission (2008a) ‘Public consultation: Legal proposal on information to patients’. Available online at: http://ec.europa.eu/enterprise/pharmaceuticals/pharmacos/docs/doc2008/2008_02/info_to_patients_consult_200802.pdf (accessed 11 May 2010).

12.

Commission (2008b) ‘Summary of the public consultation responses’, Brussels, 22 May, ENTR/F/2/UN/1c D (2008). Available online at: http://ec.europa.eu/enterprise/pharmaceuticals/patients/docs/summary_publ_cons_220508.pdf (accessed 11 May 2010).

13.

Council of the European Union (2008) ‘Council Conclusions of the 2876th Employment, Social Policy, Health and Consumer Affairs Council meeting concerning the Report on current practice with regard to provision of information to patients of medicinal products’, Press. Available online at: http://www.eu2008.si/en/News_and_Documents/Council_Conclusions/June/0609_EPSCO-patenti.pdf (accessed 11 May 2010).

14.

DTC Perspectives (2008) ‘Lawsuit over rights to DTC in Canada’. Available online at: http://www.dtcperspectives.com/article/Lawsuit-Over-Right-to-DTC-in-Canada/69.html (accessed 11 May 2010).

15.

Dyer

(2002) ‘Europe seeks to calm nerves over US-style drug advertising’, Financial Times, 23 October. Available online at: http://www.haiweb.org/campaign/DTCA/media/financialtimes231002.html (accessed 11 May 2010).

16.

EPHA (2008) EPHA consultation response: ‘Legal proposal on information to patients’. Available online at: http://www.rcplondon.ac.uk/professional-Issues/europe/Documents/EPHA%20-%20Final%20Response.pdf (accessed 11 May 2010).

17.

Frosch

Krueger

Hornik

Cronholm

and Barg

(2007) ‘Creating demand for prescription drugs: A content analysis of television direct-to-consumer advertising’, Annals of Family Medicine, 5:1, 6–13.

18.

Geyer

(2000) Exploring European Social Policy (Oxford: Polity Press).

19.

Greer

(2006) ‘Uninvited Europeanization: Neofunctionalism and the EU in health policy’, Journal of European Public Policy, 13:1, 134–152.

20.

Greer

(2009a) ‘The changing world of European health lobbies’, in Coen

and Richardson

(eds), Lobbying the European Union: Institutions, Actors and Issues (Oxford: Oxford University Press), 189–211.

21.

Greer

(2009b) The Politics of European Union Health Policies (Maidenhead: Open University Press).

22.

Guigner

(2004) ‘Institutionalizing public health in the European Commission: The thrills and spills of politicization’, in Smith

(ed.), Politics and the European Commission: Actors, Interdependence, Legitimacy (London: Routledge), 96–116.

23.

Hancher

(2010) ‘The EU pharmaceuticals market: Parameters and pathways’, in Mossialos

Permanand

Baeten

and Harvey

(eds), Health Systems Governance in Europe: The Role of European Union Law and Policy (Cambridge: Cambridge University Press), 635–682.

24.

Hauray

and Urfalino

(2009) ‘Mutual transformations and the development of European policy spaces: The case of medicines licensing’, Journal of European Public Policy, 16:1, 431–449.

25.

Hayes

(2001) ‘Is the EU edging towards DTCA?’, HAI Lights (August). Available online at: http://www.haiweb.org/pubs/hailights/aug2001/aug01_lead.html (accessed 11 May 2010).

26.

Health Alliance International (HAI) (2008) HAI Europe's Response to the EU Commission Public Consultation on Key Ideas of a Legal Proposal on Information to Patients. Available online at: http://www.haiweb.org/04042008/20080307_HAI_Europe_response_to_the_legal_proposal_on_info.pdf (accessed 11 May 2010).

27.

Hervey

and McHale

(2004) Health Law and the EU (Cambridge: Cambridge University Press).

28.

Holmer

(1999) ‘Direct-to-consumer prescription drug advertising builds bridges between patients and physicians’, Journal of the American Medical Association, 281:4, 380–382.

29.

House of Commons (2005) The Influence of the Pharmaceutical Industry: Fourth Report of Session 2004–05 (London: The Stationery Office).

30.

Huh

and Langteau

(2007) ‘Presumed influence of DTC prescription drug advertising: Do experts and novices think differently?’, Communication Research, 34:1, 25–52.

31.

Jones

and Garlick

(2003) ‘Should drug companies be allowed to talk directly to patients?’, British Medical Journal, 326:7402, 1302. Available online at: http://www.bmj.com/content/326/7402/1302.2.full.pdf (accessed 11 January 2011).

32.

Kravitz

and Bell

(2007) ‘Direct-to-consumer advertising of prescription drugs: Balancing benefits and risks, and a way forward’, Clinical Pharmacology and Therapeutics, 82:4, 360–362.

33.

Lamping

(2005) ‘European integration and health policy: A peculiar relationship’, in Steffen

(ed.), Health Governance in Europe: Issues, Challenges and Theories (London: Routledge), 18–48.

34.

Lamping

and Steffen

(2005) ‘Conclusion: The new politics of European health policy’, in Steffen

(ed.), Health Governance in Europe: Issues, Challenges and Theories (London: Routledge), 188–200.

35.

Law

(2006) Big Pharma: How the World's Biggest Drug Companies Control Illness (London: Constable).

36.

Magrini

and Font

(2007) ‘Direct to consumer advertising of drugs in Europe’, British Medical Journal, 335:7619, 526.

37.

McKee

Hervey

and Gilmore

(2010) ‘Public health policies’, in Mossialos

Permanand

Baeten

and Hervey

(eds), Health Systems Governance in Europe: The Role of European Union Law and Policy (Cambridge: Cambridge University Press), 231–281.

38.

Medawar

(2001) Health, Pharma and the EU: A Briefing for the Members of the European Parliament on Direct-to-Consumer Drug Promotion. Available online at: www.socialaudit.org (accessed 11 May 2010).

39.

Mintzes

(2006) ‘Disease mongering in drug promotion: Do governments have a regulatory role?’, PLoS Medicine, 3:4. Available online at: http://medicine.plosjournals.org/perlserv/?request=get-document&doi=10.1371/journal.pmed.0030198&ct=1 (accessed 11 May 2010).

40.

Mintzes

Barer

M. L.

Kravitz

R. L.

Kazanjian

Bassett

Lexchin

(2002) ‘Influence of direct to consumer pharmaceutical advertising and patients' requests on prescribing decisions: Two site cross sectional survey’, British Medical Journal, 324:7342, 278–279.

41.

Mossialos

Permanand

Baeten

and Harvey

(eds), (2010) Health Systems Governance in Europe: The Role of European Union Law and Policy (Cambridge: Cambridge University Press).

42.

Permanand

and Altenstetter

(2004) ‘The politics of pharmaceuticals in the European Union’, in Mossialos

Mrazek

and Walley

(eds), Regulating Pharmaceuticals in Europe: Striving for Efficiency, Equity and Quality (London: Open University Press), 38–54.

43.

Permanand

and Mossialos

(2005a) ‘Constitutional asymmetry and pharmaceutical policy-making in the European Union’, Journal of European Public Policy, 12:4, 687–709.

44.

Permanand

and Mossialos

(2005b) ‘The Europeanization of regulatory policy in the EU pharmaceutical sector’, in Steffen

(ed.), Health Governance in Europe: Issues Challenges and Theories (London: Routledge), 49–80.

45.

Prescrire (2008) ‘Patient information by pharmaceutical companies comes up against almost unanimous opposition from civil society’, Prescrire. Available online at: http://www.prescrire.org/docus/En_LetterInfoMinistersConsilium_20080605.pdf (accessed 11 May 2010).

46.

Prescrire (2010) ‘European Commission places medicines under DG-SANCO's competence’, Prescrire. Available online at: http://english.prescrire.org/spip.php?article1037 (accessed 1 June 2010).

47.

Rados

(2004) ‘Truth in advertising: Rx drug ads come of age’, USFDA Consumer Magazine. Available online at: http://www.fda.gov/fdac/features/2004/404_ads.html (accessed 11 May 2010).

48.

Randall

(2001) The European Union and Health Policy (London: Palgrave).

49.

Scharpf

(2002) ‘The European social model’, Journal of Common Market Studies, 40:4, 645–670.

50.

Shaw

(2008) ‘Direct-to-consumer advertising of pharmaceuticals’, ProQuest: Discovery Guides. Available online at: http://www.csa.com/discoveryguides/direct/review/php (accessed 11 May 2010).

51.

Smith

(2008) ‘All access points are not created equal: Explaining the fate of diffuse interests in the EU’, British Journal of Politics and International Relations, 10:1, 64–83.

52.

Stein

(2003) ‘The open method of co-ordination in the field of EU healthcare’, in Jorens

(ed.), Open Method of Co-ordination: Objectives of European Healthcare Policy (Baden-Baden: Nomos), 21–25.

53.

Vedantam

(2006) ‘Cost benefits of new schizophrenia drugs doubted’, Washington Post, 1 December. Available online at: http://www.washingtonpost.com/wp-dyn/content/article/2006/11/30/AR2006113001532.html (accessed 11 May 2010).

54.

Wilson

(1980) ‘The politics of regulation’, in Wilson

(ed.), The Politics of Regulation (New York: Basic Books Inc), 357–394.